ZA200600733B - Treatment and prevention of cardiovascular events - Google Patents
Treatment and prevention of cardiovascular eventsInfo
- Publication number
- ZA200600733B ZA200600733B ZA200600733A ZA200600733A ZA200600733B ZA 200600733 B ZA200600733 B ZA 200600733B ZA 200600733 A ZA200600733 A ZA 200600733A ZA 200600733 A ZA200600733 A ZA 200600733A ZA 200600733 B ZA200600733 B ZA 200600733B
- Authority
- ZA
- South Africa
- Prior art keywords
- prevention
- treatment
- cardiovascular events
- cardiovascular
- events
- Prior art date
Links
- 230000007211 cardiovascular event Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN604CH2003 IN206994B (xx) | 2000-10-25 | 2001-10-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200600733B true ZA200600733B (en) | 2007-07-25 |
Family
ID=34090476
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200600733A ZA200600733B (en) | 2003-07-28 | 2006-01-25 | Treatment and prevention of cardiovascular events |
Country Status (10)
Country | Link |
---|---|
US (2) | US20050026992A1 (xx) |
EP (1) | EP1648422A4 (xx) |
CN (1) | CN1822820A (xx) |
AU (1) | AU2004261212B2 (xx) |
BR (1) | BRPI0412557A (xx) |
CA (1) | CA2531279A1 (xx) |
NZ (1) | NZ544784A (xx) |
RU (1) | RU2380093C2 (xx) |
WO (1) | WO2005011586A2 (xx) |
ZA (1) | ZA200600733B (xx) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005011586A2 (en) * | 2003-07-28 | 2005-02-10 | Dr. Reddy's Laboratories, Inc. | Treatment and preventi0n of cardiovascular events |
US20090117197A1 (en) * | 2005-03-21 | 2009-05-07 | Vicus Therapeutics Llc | Compositions and methods for ameliorating cachexia |
JP5273721B2 (ja) * | 2005-03-21 | 2013-08-28 | ビカス セラピューティクス,エルエルシー | 悪液質を緩和するための組成物および方法 |
US20070009591A1 (en) * | 2005-07-07 | 2007-01-11 | Trivedi Jay S | ACE inhibitor formulation |
WO2007020079A2 (en) * | 2005-08-17 | 2007-02-22 | Synthon B.V. | Orally disintegratable simvastatin tablets |
WO2007049291A1 (en) * | 2005-10-27 | 2007-05-03 | Lupin Limited | Novel solid dosage forms of valsartan and rochlorothiazide |
MX2008006453A (es) * | 2005-11-18 | 2009-01-28 | Accu Break Technologies Inc | Formas segmentadas de dosis farmaceutica. |
US20070116756A1 (en) * | 2005-11-23 | 2007-05-24 | Dr. Reddy's Laboratories Limited | Stable pharmaceutical compositions |
US20070185065A1 (en) * | 2006-02-03 | 2007-08-09 | Vikramjit Chhokar | Combination therapy for coronary artery disease |
ES2300188B1 (es) * | 2006-05-24 | 2009-05-01 | Ferrer Internacional, S.A. | Comprimido bicapa para la prevencion de los accidentes cardiovasculares. |
WO2008001184A2 (en) * | 2006-06-26 | 2008-01-03 | Emcure Pharmaceuticals Limited | Solid composition |
US20080107726A1 (en) * | 2006-11-01 | 2008-05-08 | Pramod Kharwade | Compositions comprising beta-adrenergic receptor antagonists and diuretics |
CN101980701A (zh) * | 2008-03-28 | 2011-02-23 | 菲尔若国际公司 | 用于预防心血管疾病的胶囊 |
CN101590239B (zh) * | 2008-05-30 | 2013-03-27 | 北京奥萨医药研究中心有限公司 | 含有利尿剂、他汀和叶酸的药物组合物及其用途 |
AU2010212580B2 (en) * | 2009-02-11 | 2015-11-12 | Cadila Pharmaceuticals Ltd. | Stable pharmaceutical composition for atherosclerosis |
MX357919B (es) * | 2009-03-13 | 2018-07-25 | Nucitec Sa De Cv | Composición farmacéutica para el tratamiento de la hipercolesterolemia. |
AU2010242938A1 (en) * | 2009-04-30 | 2011-11-17 | Dr. Reddy's Laboratories Ltd. | Fixed dose drug combination formulations |
CN101897710A (zh) * | 2009-05-27 | 2010-12-01 | 北京奥萨医药研究中心有限公司 | 含有HMG-CoA还原酶抑制剂、阿司匹林、叶酸的药物组合物及其用途 |
US9056134B2 (en) * | 2010-07-21 | 2015-06-16 | Nucitec S.A. De C.V. | Single daily dosage form for prevention and treatment of metabolic syndrome |
GB201116993D0 (en) * | 2011-10-03 | 2011-11-16 | Ems Sa | Pharmaceutical compositions of antihypertensives |
RU2491070C2 (ru) * | 2011-10-11 | 2013-08-27 | Общество с ограниченной ответственностью "Фармамед" | Фармацевтическая композиция для профилактики и лечения сердечно-сосудистых заболеваний |
CN102357084B (zh) * | 2011-10-11 | 2014-02-26 | 广东彼迪药业有限公司 | 一种马来酸依那普利的片剂组合物及其制备与应用 |
CN102671198A (zh) * | 2011-12-17 | 2012-09-19 | 东莞达信生物技术有限公司 | 一种降压降脂复方药及其制备方法 |
EP2810644A1 (en) * | 2013-06-06 | 2014-12-10 | Ferrer Internacional, S.A. | Oral formulation for the treatment of cardiovascular diseases |
KR20150079373A (ko) | 2013-12-30 | 2015-07-08 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 |
PH12018502155B1 (en) * | 2016-04-20 | 2024-03-27 | Servier Lab | Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid |
CN107184952A (zh) * | 2017-06-13 | 2017-09-22 | 江苏黄河药业股份有限公司 | 一种赖诺普利复方制剂及其制备方法 |
CN110237258A (zh) * | 2018-03-09 | 2019-09-17 | 深圳奥萨制药有限公司 | 用于治疗高血压的药物组合物 |
WO2020214163A1 (en) * | 2019-04-17 | 2020-10-22 | CardioPharma, Inc. | Anti-hypertensive and cholesterol-lowering fixed-dose combination and method of manufacture |
WO2021202457A1 (en) * | 2020-03-30 | 2021-10-07 | Exagen Inc. | Cardiovascular biomarkers for systemic lupus erythematosus |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5622985A (en) | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
US6251852B1 (en) * | 1996-09-18 | 2001-06-26 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
US6235311B1 (en) | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
US6121249A (en) * | 1998-07-01 | 2000-09-19 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins |
US6323188B1 (en) * | 1998-07-01 | 2001-11-27 | Donald L. Weissman | Treatment and prevention of cardiovascular diseases, heart attack, and stroke, primary and subsequent, with help of aspirin and certain vitamins |
ES2246894T3 (es) * | 1999-08-30 | 2006-03-01 | Sanofi-Aventis Deutschland Gmbh | Ramipril para la prevencion de sucesos cardiovasculares. |
GB2361185A (en) * | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
CA2406077C (en) | 2000-04-10 | 2010-07-20 | Nicholas J. Wald | Formulation for the prevention of cardiovascular disease |
US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US6576256B2 (en) * | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US20040116510A1 (en) * | 2002-03-05 | 2004-06-17 | Nichtberger Steven A. | Antihypertensive agent and cholesterol absorption inhibitor combination therapy |
WO2003090723A1 (en) * | 2002-04-23 | 2003-11-06 | Bristol-Myers Squibb Company | Modified-release vasopeptidase inhibitor formulation, combinations and method |
MXPA04011227A (es) * | 2002-05-17 | 2005-01-25 | Esperion Therapeutics Inc | Metodos y composiciones para el tratamiento de la reperfusion isquemica. |
NZ539013A (en) * | 2002-10-03 | 2007-05-31 | Novartis Ag | Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes |
WO2004052373A1 (en) * | 2002-12-06 | 2004-06-24 | Warner-Lambert Company Llc | Benzoxazin-3-ones and derivatives thereof as inhibitors of pi3k |
AU2003303231A1 (en) * | 2002-12-20 | 2004-07-14 | Warner-Lambert Company Llc | Benzoxazines and derivatives thereof as inhibitors of pi3ks |
TW200503994A (en) * | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
ES2331131T3 (es) * | 2003-05-20 | 2009-12-22 | Novartis Ag | Heterociclos de nitrogeno n-acil como ligandos de los receptores activados por los proliferadores de las peroximas. |
JP2009513523A (ja) * | 2003-07-08 | 2009-04-02 | ノバルティス アクチエンゲゼルシャフト | ベンゼンスルホニルアミノ化合物およびそれらを含む医薬組成物 |
WO2005011586A2 (en) * | 2003-07-28 | 2005-02-10 | Dr. Reddy's Laboratories, Inc. | Treatment and preventi0n of cardiovascular events |
US20050053648A1 (en) * | 2003-09-08 | 2005-03-10 | Chalmers Anne Marie | Medication delivery device |
US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
US20070116756A1 (en) * | 2005-11-23 | 2007-05-24 | Dr. Reddy's Laboratories Limited | Stable pharmaceutical compositions |
-
2004
- 2004-07-28 WO PCT/US2004/024324 patent/WO2005011586A2/en active Application Filing
- 2004-07-28 AU AU2004261212A patent/AU2004261212B2/en not_active Ceased
- 2004-07-28 CA CA002531279A patent/CA2531279A1/en not_active Abandoned
- 2004-07-28 EP EP20040779390 patent/EP1648422A4/en not_active Withdrawn
- 2004-07-28 US US10/898,549 patent/US20050026992A1/en not_active Abandoned
- 2004-07-28 NZ NZ544784A patent/NZ544784A/en not_active IP Right Cessation
- 2004-07-28 BR BRPI0412557-6A patent/BRPI0412557A/pt not_active Application Discontinuation
- 2004-07-28 RU RU2006102356/15A patent/RU2380093C2/ru not_active IP Right Cessation
- 2004-07-28 CN CNA2004800204130A patent/CN1822820A/zh active Pending
-
2006
- 2006-01-25 ZA ZA200600733A patent/ZA200600733B/xx unknown
-
2009
- 2009-11-19 US US12/621,628 patent/US20100068269A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20100068269A1 (en) | 2010-03-18 |
NZ544784A (en) | 2009-11-27 |
WO2005011586A3 (en) | 2005-07-07 |
EP1648422A2 (en) | 2006-04-26 |
EP1648422A4 (en) | 2007-09-19 |
AU2004261212A1 (en) | 2005-02-10 |
CA2531279A1 (en) | 2005-02-10 |
AU2004261212B2 (en) | 2011-01-27 |
WO2005011586A2 (en) | 2005-02-10 |
US20050026992A1 (en) | 2005-02-03 |
BRPI0412557A (pt) | 2006-09-19 |
CN1822820A (zh) | 2006-08-23 |
RU2006102356A (ru) | 2007-09-10 |
RU2380093C2 (ru) | 2010-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200600733B (en) | Treatment and prevention of cardiovascular events | |
TWI347188B (en) | Treatment and prevention of osteoporosis | |
AU2003290548A8 (en) | Prevention and treatment of synucleinopathic disease | |
SI2075000T1 (sl) | Kombinacija azelastina in ciklezonida | |
HK1152474A1 (en) | Methods and compositions for the prevention and treatment of sepsis | |
IL178996A0 (en) | Thienopyridinone compounds and methods of treatment | |
IL182436A0 (en) | Thienopyridinone compounds and methods of treatment | |
AU2003291480A8 (en) | Composition for the prevention and treatment of inflammation of the ear | |
IL149251A0 (en) | Diagnosis and treatment of cardiovascular conditions | |
GB2407823B (en) | Surface treatment of magnesium and its alloys | |
EP1786265A4 (en) | NEW COMPOSITIONS AND PROCESSING METHODS | |
AU2002359747A8 (en) | Prevention and treatment of atherosclerosis and restenosis | |
GB0324523D0 (en) | Compositions and methods of treatment | |
AU2003301819A8 (en) | Compositions and methods for prevention of photoaging | |
AU2003231279A8 (en) | Prevention and treatment of type 2 diabetes | |
EP1560592A4 (en) | TREATMENT OF ALLGIELES | |
EP1573063A4 (en) | TREATMENT OF LIVER DISEASES | |
GB0221712D0 (en) | Methods of treatment | |
IL166083A0 (en) | Methods for treatment and prevention of gastrointestinal conditions | |
GB0419175D0 (en) | Method of treatment and compositions | |
IL151658A0 (en) | Methods and compositions for the treatment or prevention of cardiovascular diseases | |
AU2003251751A8 (en) | Agents capable of inhibiting ras and uses thereof | |
AU2003276123A8 (en) | Treatment of uveal melanoma | |
GB0305699D0 (en) | Therapeutic compositions and methods | |
AU2003213256A8 (en) | Treatment and prevention of aids progression and methods of using same |